Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 246Other solid neoplasm 29CNS 15Gastrointestinal 14Tumor-Agnostic 11Gynecologic 9Head & Neck 7Dermatologic 7Genitourinary 5Breast 3Sarcoma 2Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Meningeal Carcinomatosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pemetrexed × Breast × 1 year × Clear all
NCT03396445 2025-11-05

MK-5890-001

Merck Sharp & Dohme LLC

Phase 1 Completed
182 enrolled 36 charts
BreastThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT05315700 2025-08-05

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

ORIC Pharmaceuticals

Phase 1/2 Recruiting
350 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡